Tanapoxvirus lacking the 15L gene inhibits melanoma cell growth in vitro by inducing interferon-λ1 release

Zhang, Tiantian; Essani, Karim

doi:10.1007/s11262-017-1434-2

Cited by 4 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunotherapy has been proven to be a groundbreaking approach in cancer treatment via harnessing the body's own immune system to combat tumors. Aiming at enhancing the immune system's ability to recognize and target cancer cells, examples of current immunotherapy include checkpoint inhibitors, adoptive T cell therapy (including CAR-T cell therapy), and oncolytic virotherapy [26,41]. Neoantigens, known for their high immunogenicity, possess significant potential to elicit a robust immune response.…”

Section: Studies Of Neoantigens In Immunotherapymentioning

confidence: 99%

Neoantigens: The Novel Precision Cancer Immunotherapy

Zhang,

Kurban,

Wang

2023

Biologics

Self Cite

View full text Add to dashboard Cite

The past few decades have witnessed the remarkable progress of cancer immunotherapy. Neoantigens, also known as tumor-specific antigens, are novel antigens originating from tumor-specific alterations such as genomic mutations, dysregulated RNA splicing, and post-translational modifications. Neoantigens, recognized as non-self entities, trigger immune responses that evade central and peripheral tolerance mechanisms. With the notable strides in cancer genomics facilitated by next-generation sequencing technologies, neoantigens have emerged as a promising avenue for tumor-specific immunotherapy grounded in genomic profiling-based precision medicine. Furthermore, a growing number of preclinical and clinical investigations are harnessing the potential synergies between neoantigens and other immunotherapies such as adoptive cell therapy and immune checkpoint inhibitors. In this review, we will provide a comprehensive perspective encompassing the trajectory of neoantigens, neoantigen design strategies, and the diverse array of clinical applications inherent in immunotherapy strategies centered around neoantigens. Moreover, we delve into the inherent prospects and challenges that accompany the clinical adoption of neoantigen-based immunotherapies while also putting forth potential solutions to address these challenges.

show abstract

Section: Studies Of Neoantigens In Immunotherapymentioning

confidence: 99%

Neoantigens: The Novel Precision Cancer Immunotherapy

Zhang,

Kurban,

Wang

2023

Biologics

Self Cite

View full text Add to dashboard Cite

show abstract

“…40,[47][48][49] The list of viruses that demonstrate oncolytic activity keeps expanding and includes agents of animal (e.g., vaccinia virus [VV]) and human (e.g., serotype 3 reovirus, type 1 herpes simplex virus [HSV-1]) origin. [50][51][52][53][54][55][56][57][58][59][60][61][62][63][64] Tumor selectivity, referred to as 'oncotropism', requires that cancer cells i) express the virus entry receptor and ii) demonstrate permissiveness to virus life cycle completion. [65][66][67][68][69] Alongside, OVs should undergo abortive infection in most normal tissues to prevent side effects and toxicity, which is of particular concern when treating immunosuppressed patients.…”

Section: Introductionmentioning

confidence: 99%

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

et al. 2018

View full text Add to dashboard Cite

Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.

show abstract

Neutralization of matrix metalloproteinase-9 potentially enhances oncolytic efficacy of tanapox virus for melanoma therapy

et al. 2017

View full text Add to dashboard Cite

Matrix metalloproteinases (MMPs), which are involved in degradation of extracellular matrix, are critical regulators in tumor progression, metastasis and angiogenesis. Although induction of MMPs is frequently observed during the viral infection, the effect of MMPs on viral replication varies between viruses. MMP-9, for instance, is upregulated and promotes the replication of some viruses, such as herpes simplex virus, but inhibits the replication of others. Here, we report that infection with tanapox virus (TPV) promotes the expression of MMP-9 in the melanoma cells. In addition, we show that MMP-9 exerts an anti-viral effect on TPV replication and plays a protective role in TPV-infected melanoma cells in vitro. Moreover, the neutralization of MMP-9 in melanoma cells remarkably enhances the TPV infection and leads to a significant reduction in cell survival. In summary, this study contributes to understanding of the role played by MMP-9 in TPV infectivity and provides more insights for using TPV as cancer virotherapy in future studies. Since TPV has shown substantial oncolytic efficacy in promoting melanoma tumor regression in animal models, identifying mechanisms that suppress MMP-9 expression upon TPV infection can potentially improve its use as a melanoma virotherapy.

show abstract

Tanapoxvirus lacking the 15L gene inhibits melanoma cell growth in vitro by inducing interferon-λ1 release

Cited by 4 publications

References 40 publications

Neoantigens: The Novel Precision Cancer Immunotherapy

Neoantigens: The Novel Precision Cancer Immunotherapy

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Neutralization of matrix metalloproteinase-9 potentially enhances oncolytic efficacy of tanapox virus for melanoma therapy

Contact Info

Product

Resources

About